Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Brimonidine
Phase 3Completed 0 watching 0 views this week๐ Rising
69
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Presbyopia
Conditions
Presbyopia, Refractive Error, Eye Diseases, Near Vision
Trial Timeline
Dec 19, 2022 โ Jan 25, 2024
NCT ID
NCT05656027About Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Brimonidine
Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Brimonidine is a phase 3 stage product being developed by LENZ Therapeutics for Presbyopia. The current trial status is completed. This product is registered under clinical trial identifier NCT05656027. Target conditions include Presbyopia, Refractive Error, Eye Diseases.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05656027 | Phase 3 | Completed |
Competing Products
14 competing products in Presbyopia
Other Products from LENZ Therapeutics
Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Placebo (Vehicle) ophthalmic solutionPhase 3
69
Aceclidine+Brimonidine combination ophthalmic solution + Placebo + Aceclidine Ophthalmic SolutionPhase 3
69
Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + VehiclePhase 3
69
Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Vehicle Proprietary Ophthalmic SolutionPhase 2
44
PRX-100 + PlaceboPhase 2
44